203 related articles for article (PubMed ID: 2771993)
1. The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
Brosman S
Prog Clin Biol Res; 1989; 310():193-205. PubMed ID: 2771993
[No Abstract] [Full Text] [Related]
2. Long-term effect of intravesical bacillus Calmette-Guérin (BCG) Tice strain on flat carcinoma in situ of the bladder.
Reitsma DJ; Guinan P; Lamm DL; Khanna OP; Brosma SA; DeKernion JB; Williams RD; Sipmson G; Hanna MG
Prog Clin Biol Res; 1989; 310():171-85. PubMed ID: 2672014
[No Abstract] [Full Text] [Related]
3. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ
Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
[No Abstract] [Full Text] [Related]
4. A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer.
Brosman SA; Lamm DL; van der Meijden AP; Debruyne FM
Prog Clin Biol Res; 1989; 310():311-23. PubMed ID: 2672019
[TBL] [Abstract][Full Text] [Related]
5. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands.
Witjes WP; van der Meijden PM; Roos EP; Witjes JA; Steerenberg PA; Doesburg W; Debruyne FM
Prog Clin Biol Res; 1992; 378():59-67. PubMed ID: 1301587
[No Abstract] [Full Text] [Related]
6. [Treatment and follow-up of superficial bladder cancer].
Raitanen M
Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
[No Abstract] [Full Text] [Related]
7. Evaluation of clinical data in bladder cancer immunotherapy with Connaught BCG (ImmuCyst).
Barreto L; Csizer Z; Sparkes JD
Dev Biol Stand; 1992; 77():229-31. PubMed ID: 1426667
[TBL] [Abstract][Full Text] [Related]
8. Percutaneous, oral, or intravesical BCG administration: what is the optimal route?
Lamm DL; Sarodosy MS; DeHaven JI
Prog Clin Biol Res; 1989; 310():301-10. PubMed ID: 2672018
[No Abstract] [Full Text] [Related]
9. Bacillus Calmette-Guérin immunotherapy. Techniques and results.
Brosman SA
Urol Clin North Am; 1992 Aug; 19(3):557-64. PubMed ID: 1636239
[TBL] [Abstract][Full Text] [Related]
10. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
11. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
12. BCG for bladder cancer.
Med Lett Drugs Ther; 1991 Apr; 33(841):29-30. PubMed ID: 2002783
[No Abstract] [Full Text] [Related]
13. BCG vaccine in urinary bladder cancer.
Brosman SA
West J Med; 1991 Dec; 155(6):633. PubMed ID: 1812634
[No Abstract] [Full Text] [Related]
14. [Our experience in the treatment of superficial cancer of the bladder with BCG].
Martínez E; Díaz I; Salvador J; Viladoms JM; Zungri E; Solé-Balcells FJ
Arch Esp Urol; 1989 May; 42(4):325-7. PubMed ID: 2782959
[TBL] [Abstract][Full Text] [Related]
15. BCG treatment in Tis of the urinary bladder, results of the EORTC Protocol 30861. EORTC GU Group.
Jakse G; Hall R; Bono A; Höltl W; Carpentier P; de Pauw M; Sylvester R
Prog Clin Biol Res; 1992; 378():69-74. PubMed ID: 1301588
[No Abstract] [Full Text] [Related]
16. Intravesical BCG therapy in patients with superficial bladder tumors.
Steg A; Belas M; Leleu C; Boccon-Gibod L
Prog Clin Biol Res; 1989; 310():153-60. PubMed ID: 2771990
[No Abstract] [Full Text] [Related]
17. Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract.
Hayashida Y; Nomata K; Noguchi M; Eguchi J; Koga S; Yamashita S; Hayashi M; Kanatake H
Urology; 2004 Jun; 63(6):1084-8. PubMed ID: 15183955
[TBL] [Abstract][Full Text] [Related]
18. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
Rintala E; Jauhiainen K; Alfthan O
Prog Clin Biol Res; 1989; 310():271-4. PubMed ID: 2505270
[No Abstract] [Full Text] [Related]
19. Intravesical therapy for superficial bladder cancer.
Malkowicz SB
Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
[TBL] [Abstract][Full Text] [Related]
20. Management of superficial transitional cell carcinoma of the bladder.
Fleischmann J; Goldberg G
Semin Urol; 1993 Nov; 11(4):193-204. PubMed ID: 8290825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]